ライフサイエンスコーパス: monoclonal

1 odies or extend the half-life of therapeutic monoclonals.

2 This mutation rendered MuPyV resistant to a monoclonal Ab (mAb), whose specificity overlapped the en

3 In this study, a structurally-defined human monoclonal alloantibody was employed to provide a mechan

4 s of this regimen with the addition of novel monoclonal and bispecific antibody constructs targeting

5 ificity of twenty one commercially available monoclonal and polyclonal antibodies against ZIKV and DE

6 her demonstrated that exposure in utero to a monoclonal anti-Caspr2 antibody, derived from a mother o

7 egatively charged liposomes and with MBB2, a monoclonal anti-DI antibody that recapitulates most of t

8 In addition, we generated a new monoclonal anti-Siglec-15 Ab to clarify its expression p

9 The results of this study suggest that a monoclonal anti-stalk approach to prevent or treat influ

10 Though polyclonal and monoclonal antibodies (Ab) can provide complete protecti

11 ecently, numerous broadly neutralizing HIV-1 monoclonal antibodies (bNAbs) have been developed that p

12 of the potent HA stalk broadly neutralizing monoclonal antibodies (bNAbs).

13 ve is provided by using broadly neutralizing monoclonal antibodies (bnAbs).

14 an approach utilizing synthetic DNA-encoded monoclonal antibodies (dmAbs) for direct in vivo product

15 , routinely used for the characterization of monoclonal antibodies (enzyme-linked immunosorbent assay

16 haracterized for binding to a panel of human monoclonal antibodies (HMAbs) and the coreceptor CD81 to

17 produces the culture supernatant containing monoclonal antibodies (IgG(1)).

18 Previous M2e-specific monoclonal antibodies (M2e-MAbs) show protective potenti

19 trode interface promotes the localization of monoclonal antibodies (mAb) selective for binding the ep

20 ch harness the high targeting specificity of monoclonal antibodies (mAb) with the potency of small mo

21 Here, we generate patient-derived monoclonal antibodies (mAbs) against LGI1.

22 ne hybridoma technology to generate 25 mouse monoclonal antibodies (MAbs) against the GPC of MACV.

23 covery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spik

24 , common components of storage solutions for monoclonal antibodies (mAbs) and ADCs, such as nonvolati

25 d intranasal gepants and the injectable CGRP monoclonal antibodies (mAbs) are described, as are recen

26 More than 100 monoclonal antibodies (mAbs) are in industrial and clini

27 Antiviral human monoclonal antibodies (mAbs) are promising candidates fo

28 Anti-CD40 monoclonal antibodies (mAbs) comprise agonists and antag

29 By analyzing more than 500 monoclonal antibodies (mAbs) derived from B cells induce

30 Monoclonal antibodies (mAbs) derived from these plasmabl

31 post-translational modifications [PTMs]) of monoclonal antibodies (mAbs) during drug development.

32 Among 598 human monoclonal antibodies (mAbs) from 10 COVID-19 patients,

33 We previously isolated a large panel of monoclonal antibodies (mAbs) from B cells of a human sur

34 ecific, hemagglutination inhibition-inactive monoclonal antibodies (MAbs) from elderly individuals.

35 Although therapeutic monoclonal antibodies (mAbs) have demonstrated significa

36 lational modifications (PTMs) in therapeutic monoclonal antibodies (mAbs) is essential during their p

37 Here, we characterize human monoclonal antibodies (mAbs) isolated from a survivor of

38 ericidal activity induced by combinations of monoclonal antibodies (mAbs) raised against factor H-bin

39 enic HPV genotypes by using a large panel of monoclonal antibodies (MAbs) raised against the L1 prote

40 ntial for rapid advancement into the clinic, monoclonal antibodies (mAbs) represent a highly promisin

41 Monoclonal antibodies (mAbs) represent a rapidly expandi

42 n undetermined, in part because of a lack of monoclonal antibodies (mAbs) that can distinguish these

43 Here, we isolated and characterized human monoclonal antibodies (mAbs) that target IBV NA from an

44 We aimed to characterize eight anti-PSA monoclonal antibodies (mAbs) to assess the prostate canc

45 zed, non-Fcgamma receptor (FcgammaR)-binding monoclonal antibodies (mAbs) to CD3 have antileukemic pr

46 tibody responses, we produced 28 antiadhesin monoclonal antibodies (MAbs) to representative adhesins

47 re used for the generation of nonimmunogenic monoclonal antibodies (MAbs), and characterization of su

48 used analytical tool in characterization of monoclonal antibodies (mAbs).

49 ith KD 1-3 weeks after onset and prepared 60 monoclonal antibodies (mAbs).

50 ical studies and the analysis of many murine monoclonal antibodies (MAbs).

51 protein therapeutics and in particular IgG1 monoclonal antibodies (mAbs).

52 p120 V2 is inhibited by anti-alpha(4)beta(7) monoclonal antibodies (mAbs).

53 e identify three CVA16-specific neutralizing monoclonal antibodies (nAbs) with therapeutic potential:

54 Monoclonal antibodies (targeting CD3, CD20, CD138, and C

55 overy of clinically applicable high affinity monoclonal antibodies against a broad range of targets.

56 map the fine structure of the epitopes of 28 monoclonal antibodies against amyloid-beta using immunos

57 ting the pairwise combination of 11 parental monoclonal antibodies against CD73 was generated by Fab-

58 While the therapeutic benefit of monoclonal antibodies against infectious disease agents

59 We show that human monoclonal antibodies against NA induced by vaccination

60 e investigated two fully human, neutralizing monoclonal antibodies against severe acute respiratory s

61 therapy with plasma from recovered patients, monoclonal antibodies against the viral S-protein, and s

62 tralization by receptor-binding domain (RBD) monoclonal antibodies and convalescent sera from people

63 sted several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have ap

64 Monoclonal antibodies and hyperimmune globulin may provi

65 mon serious toxicity after administration of monoclonal antibodies and immune effector cell therapies

66 the ability to target B cells with anti-CD20 monoclonal antibodies and plasma cells with proteasome i

67 d cell adhesive properties of CD31, specific monoclonal antibodies and recombinant proteins were rega

68 the elution behavior of various therapeutic monoclonal antibodies and their fragments (25-150 kDa) h

69 igns of affinity maturation, gut-derived IgA monoclonal antibodies are cross-reactive in the sense th

70 Monoclonal antibodies are desirable alternatives, but no

71 Virus-neutralizing monoclonal antibodies are predicted to reduce viral load

72 Several of these monoclonal antibodies are promising candidates for clini

73 Anti-CD20 monoclonal antibodies are widely used for the treatment

74 Our findings reinforce the power of monoclonal antibodies as tools to interrogate structure-

75 sed the efficacy and safety of the antitoxin monoclonal antibodies bezlotoxumab and actoxumab in part

76 rization of typhoid toxin-neutralizing human monoclonal antibodies by immunizing genetically engineer

77 lengths and tested them with polyclonal and monoclonal antibodies by inhibition enzyme-linked immuno

78 ral and functional studies, we show that the monoclonal antibodies can be clustered into classes that

79 deployed, the rapidity with which antiviral monoclonal antibodies can be isolated and engineered off

80 at might limit the therapeutic usefulness of monoclonal antibodies can be mitigated by the use of ant

81 Monoclonal antibodies can mediate protection against Ebo

82 covery and development of virus-neutralizing monoclonal antibodies could be one approach to treat or

83 al virus (RSV), and several RSV vaccines and monoclonal antibodies currently in clinical trials, unde

84 Monoclonal antibodies derived from these clones show inc

85 otherapies such as the use of vaccination or monoclonal antibodies directed against aggregated, toxic

86 Monoclonal antibodies directed against proprotein conver

87 IL-6-directed therapeutics include monoclonal antibodies directed at IL-6, the IL-6 recepto

88 From Monoclonal Antibodies for C. difficile Therapy II, no pa

89 tested using placebo group data from MODIFY (Monoclonal Antibodies for C. difficile Therapy) I and II

90 rt that Fc engineering of anti-influenza IgG monoclonal antibodies for selective binding to the activ

91 characterize a panel of plasmablast-derived monoclonal antibodies from an infected child whose antib

92 olation of sixty-one SARS-CoV-2-neutralizing monoclonal antibodies from five patients infected with S

93 Numerous monoclonal antibodies have been developed successfully f

94 sed interest in malaria elimination, TBV and monoclonal antibodies have moved to the center stage of

95 Here, we discuss targets of monoclonal antibodies in mosquito sexual stages of Plasm

96 However, biologic agents interfering with monoclonal antibodies is not widely considered.

97 tivity of both convalescent plasma and human monoclonal antibodies measured using each virus correlat

98 re mapped using milk-specific human sera and monoclonal antibodies on overlapping and recombinant pep

99 toneal injection of anti-SQSTM1-neutralizing monoclonal antibodies or conditional depletion of Insr i

100 N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be read

101 st-translational modification of therapeutic monoclonal antibodies produced in mammalian cells and is

102 largest class of biotherapeutics, with five monoclonal antibodies ranked in the top 10 blockbuster d

103 Moreover, the generation of monoclonal antibodies recognizing IGLV3-21 or mutated IG

104 Many therapeutic monoclonal antibodies require binding to Fc gamma recept

105 ID-19-convalescent patients and neutralizing monoclonal antibodies specific to SARS-CoV-2 antigens ca

106 x in vitro against invasion inhibitory human monoclonal antibodies targeting a conserved binding doma

107 out to be particularly evident, a number of monoclonal antibodies targeting IL-17 pathways have been

108 designed an immunogen to generate the first monoclonal antibodies targeting Tspan15, a model TspanC8

109 -independent neutralization by a panel of gB monoclonal antibodies than a wild-type gC rescuant virus

110 Thus, monoclonal antibodies that bind a pan-amyloid epitope ha

111 Immune checkpoint inhibitors (ICIs), monoclonal antibodies that block the immune-regulatory "

112 Here we describe several monoclonal antibodies that target the S glycoprotein of

113 Here we analyse a large panel of human monoclonal antibodies that target the spike (S) glycopro

114 We used cell-specific monoclonal antibodies to eliminate neutrophils, monocyte

115 or-specific CD8 T cells, and with anticancer monoclonal antibodies to increase ADCC and antitumor eff

116 ultiplexed site-specific PTM quantitation of monoclonal antibodies to overcome this limitation.

117 A) is based on the principle that binding of monoclonal antibodies to specific epitopes of T. b.

118 Purification of therapeutic monoclonal antibodies usually involves a protein A affin

119 We identified several monoclonal antibodies with strong in vitro and in vivo t

120 ugates from innovative synthetic haptens and monoclonal antibodies with subnanomolar affinity.

121 es, and non-allergen-specific therapies (eg, monoclonal antibodies) are being explored.

122 ort had induction therapy with polyclonal or monoclonal antibodies, 28% did not receive calcineurin i

123 Such therapeutics include peptides, monoclonal antibodies, antibody fragments and nontraditi

124 Most newly developed biologics, including monoclonal antibodies, are structurally complex and are

125 Two potently neutralizing monoclonal antibodies, COV2-2196 and COV2-2130, which re

126 omplement-targeted immunotherapies including monoclonal antibodies, fusion proteins and peptidomimeti

127 nd antigenicity analysis with a panel of six monoclonal antibodies, including antibodies that recogni

128 lls with proteasome inhibitors and anti-CD38 monoclonal antibodies, it is increasingly important to d

129 T) or mutant human INSR Two murine anti-INSR monoclonal antibodies, previously shown to be surrogate

130 Although not restricted to monoclonal antibodies, this approach is called (89)Zr-im

131 For seven monoclonal antibodies, this study investigates the obser

132 Here, with the help of new monoclonal antibodies, we directly identified a T cell p

133 lls, we generated several HPV-specific human monoclonal antibodies, which exhibited a high degree of

134 s, it is currently solely based on expensive monoclonal antibodies, which often inflict immune-relate

135 e of Notch1 short interference RNA or Notch1 monoclonal antibodies, which produce a more specific blo

136 on and predominantly encoded strain-specific monoclonal antibodies, which suggests a naive B cell ori

137 able of neutralizing virus when expressed as monoclonal antibodies.

138 ability samples, and trisulfide standards of monoclonal antibodies.

139 apsids to impact recognition by neutralizing monoclonal antibodies.

140 hibit markedly higher thermal stability than monoclonal antibodies.

141 variants with affinities that rival those of monoclonal antibodies.

142 cterized using a panel of intertype-reactive monoclonal antibodies.

143 rapidly identify and characterize protective monoclonal antibodies.

144 nding site for several previously identified monoclonal antibodies.

145 and to developing vaccines, antivirals, and monoclonal antibodies.

146 ssays that tracked 170 APOL1 domain-specific monoclonal antibodies.

147 (KD range: 0.399-233 nM) of CD160 targeting monoclonal antibodies.

148 rovide an initial screen for all therapeutic monoclonal antibodies.

149 itope affinity for two groups of widely used monoclonal antibodies.

150 Using a plasmid encoding an anti-poxvirus monoclonal antibody (as a reporter of protein expression

151 of 0.58 kDa rhodamine and 153 kDa anti-VEGF monoclonal antibody (bevacizumab) upon IA injection.

152 mbination with a suboptimal dose of anti-CD3 monoclonal antibody (combined therapy [CT], 1 x 5 mug [C

153 Immunotherapy with anti-CD38 monoclonal antibody (daratumumab) was proposed with a cl

154 Monoclonal antibody (mAb) 10E8 recognizes a highly conse

155 Anti-LOS monoclonal antibody (MAb) 2C7, a promising antigonococca

156 Measurement of monoclonal antibody (mAb) binding affinity to DIII prote

157 ying the composition of protective antiviral monoclonal antibody (mAb) cocktails are poorly defined.

158 Furthermore, therapeutic monoclonal antibody (mAb) could be quantified by our met

159 ber can reduce the abundance of low-affinity monoclonal antibody (mAb) epitopes while retaining high-

160 Binding to either an anti-mouse IL-2 monoclonal antibody (mAb) or a small molecule inhibitor

161 ifferent genotoxic cytostatics and anti-CD20 monoclonal antibody (mAb) rituximab.

162 ut of this assay to the discovery of a novel monoclonal antibody (mAb) sandwich pair for the detectio

163 uate the potential of SEC-CIU to distinguish monoclonal antibody (mAb) subclasses, illustrating the e

164 rated anti-bacterial efficacy of a humanised monoclonal antibody (mAb) targeting the O25b O-antigen o

165 Monoclonal antibody (mAb) technology is an excellent too

166 Here, we developed an anti-AQP3 monoclonal antibody (mAb) that inhibited AQP3-facilitate

167 ciated with the discovery and development of monoclonal antibody (mAb) therapeutics is the determinat

168 ent forms, it is important to use a specific monoclonal antibody (mAb) to characterize these molecule

169 Here, we report that one human monoclonal antibody (MAb), 53C10, isolated from transchr

170 Here, we report a monoclonal antibody (mAb), MW05, with SARS-CoV-2 neutral

171 is study, we investigated how a neutralizing monoclonal antibody (MAb), which targets the receptor-bi

172 ne well-studied, strongly neutralizing human monoclonal antibody (mAb).

173 ture of native bovine IRBP in complex with a monoclonal antibody (mAb5) by cryo-electron microscopy,

174 ted in vitro two Frd7 blocking strategies: a monoclonal antibody (mAbFzd7) against Fzd7 and a soluble

175 his methodology to the study of HCPs in NIST monoclonal antibody (NISTmAb), more than 150 HCPs were c

176 structure of the broadly neutralizing human monoclonal antibody 3G12 bound to the RSV G central cons

177 cytopenia using the rat anti-mouse GPIbalpha monoclonal antibody 5A7, generated in our laboratory.

178 nd functional efficacy of the N-CSP-specific monoclonal antibody 5D5.

179 tological analysis showed some uptake of the monoclonal antibody after IA delivery, and OBBBO signifi

180 us and intravenous evinacumab, a fully human monoclonal antibody against angiopoietin-like 3, are not

181 Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential

182 haracterize ARGX-117, a humanized inhibitory monoclonal antibody against complement C2.

183 Dupilumab, a VelocImmune-derived human monoclonal antibody against the interleukin (IL) 4 recep

184 were treated with spartalizumab, a humanized monoclonal antibody against the programmed death-1 (PD-1

185 ed the protective efficacy of a neutralizing monoclonal antibody and found that pretreatment, even in

186 in the N-glycan profile of a biotherapeutic monoclonal antibody and was able to achieve sensitive gl

187 ate this approach, we show that binders to a monoclonal antibody are identified in proportion to libr

188 Pretreatment with a uPAR monoclonal antibody attenuated kidney injury in suPAR-ov

189 y human, CD40 pathway blocking, nondepleting monoclonal antibody being developed as an immunosuppress

190 Monoclonal antibody binding inhibits this conformational

191 Lastly, monoclonal antibody blockade of SEMA4C in vitro mirrored

192 Leronlimab, a monoclonal antibody blocker of CCR5 originally developed

193 The EGFR monoclonal antibody cetuximab is generally used in combi

194 form for comparative characterization of the monoclonal antibody Cetuximab.

195 gest a clinically relevant impact of IVIg on monoclonal antibody clearance and indirectly hint at an

196 s been addressed by developing an antirabies monoclonal antibody cocktail.

197 ently tested with samples of anti-SARS-CoV-2 monoclonal antibody CR3022 (0.1 mug/ml, 1.0 mug/ml, 10 m

198 We find that the monoclonal antibody CR3022 binds the RBD tightly, neutra

199 Evolocumab, a fully human monoclonal antibody directed against proprotein converta

200 Fabs offer an attractive platform for monoclonal antibody discovery/engineering, but library c

201 is, while its pharmaceutical inhibition by a monoclonal antibody has been approved for the treatment

202 EV) were successfully treated with anti-VEEV monoclonal antibody Hu1A3B-7 delivered in glucosamine-co

203 The thermal unfolding of a recombinant monoclonal antibody IgG1 (mAb) was measured with differe

204 e regression, Tregs were depleted using CD25 monoclonal antibody in atherosclerotic mice during apoli

205 ted therapy supports the hypothesis that the monoclonal antibody is causal and pathogenic.

206 A monoclonal antibody KKO which binds to PF4-NET complexes

207 A therapeutic immunoglobulin (Ig) G(1) monoclonal antibody lost more than half of its ADCC acti

208 Monoclonal antibody LY-CoV555, when coadministered with

209 The monoclonal antibody m102.4 binds to the immunodominant N

210 the typical form of gI, as a previously used monoclonal antibody mAb3104 and a newly made peptide ant

211 have been used to add and remove fucose from monoclonal antibody N-glycans, with significant impacts

212 the anti-programmed cell death-1 (anti-PD-1) monoclonal antibody nivolumab, has shown efficacy in tum

213 logies, which can be attenuated by anti-ApoE monoclonal antibody or deletion of ApoE via its specific

214 imaging the binding of a protease-activated monoclonal antibody prodrug, called a Probody((R)) thera

215 In conclusion, the Ca37 monoclonal antibody proved to be effective against C. al

216 Passive transfer of a neutralizing monoclonal antibody reduced viral burden in the lung and

217 notherapy of leukemia and lymphoma using the monoclonal antibody rituximab.

218 signed to optimize HCP detection in purified monoclonal antibody samples with LC-MS(2).

219 Golimumab is a human monoclonal antibody specific for tumor necrosis factor a

220 systematically evaluated using an anti-CD22 monoclonal antibody spiked into monkey and human serum,

221 Daratumumab is a human monoclonal antibody targeting CD38, an antigen uniformly

222 nd efficacy of belimumab, a fully human IgG1 monoclonal antibody targeting the cytokine B cell-activa

223 Satralizumab, a humanised monoclonal antibody targeting the interleukin-6 receptor

224 Through study of a neutralizing monoclonal antibody termed mAb P-4G2, which neutralizes

225 d pharmacodynamics (PD) of the human anti-C5 monoclonal antibody tesidolumab (LFG316) in end-stage re

226 Ofatumumab is an anti-CD20 monoclonal antibody that binds to the small extracellula

227 fants of 1 or 2 doses of suptavumab, a human monoclonal antibody that can bind and block a conserved

228 208) is an Fc-enhanced, humanised, anti-CD19 monoclonal antibody that has shown preclinical and singl

229 Osocimab is a long-acting, fully human monoclonal antibody that inhibits factor XIa.

230 Hu11B6 is a monoclonal antibody that internalizes in cells expressin

231 We assessed bimekizumab, a monoclonal antibody that selectively neutralises IL17A a

232 Daratumumab is a monoclonal antibody that targets CD38, an antigen expres

233 Daratumumab, a human monoclonal antibody that targets CD38, depletes plasma c

234 lind, Phase II placebo-controlled trial of a monoclonal antibody that targets the HA stalk (CR6261) i

235 Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL-4 receptor alpha

236 Nivolumab, a monoclonal antibody therapeutic approved by the FDA, bin

237 critical role of isotype for an influenza A monoclonal antibody therapeutic.

238 In experimental studies, we used a monoclonal antibody to urokinase plasminogen activator r

239 In addition to labeling the monoclonal antibody trastuzumab with excellent cysteine-

240 val in melanoma patients undergoing anti-PD1 monoclonal antibody treatment.

241 ulin Fc (IL22Fc) fusion protein and anti-p40 monoclonal antibody treatments, respectively.

242 fter four days, up to 30 ng/mL of functional monoclonal antibody were detected in the serum of rabbit

243 Nirsevimab is a monoclonal antibody with an extended half-life that is b

244 Here, we show that a human monoclonal antibody with pan-amyloid-binding activity (m

245 argetuximab plus pembrolizumab (an anti-PD-1 monoclonal antibody) in previously treated patients with

246 Here we report a therapeutic antagonistic monoclonal antibody, 3P10, that targets GFRAL and inhibi

247 d characterization of such MAbs revealed one monoclonal antibody, 53C10, exhibiting a potent neutrali

248 d was further confirmed by analyzing another monoclonal antibody, bevacizumab, as well as a soluble a

249 , which was blocked completely by an anti-C5 monoclonal antibody, but not by a factor D inhibitor, in

250 LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease

251 ab, a high-affinity interleukin-17A (IL-17A) monoclonal antibody, has previously shown efficacy in ra

252 and characterize a cross-reactive human IgA monoclonal antibody, MAb362.

253 Here, by employing a novel monoclonal antibody, the authors found that the 24-kDa L

254 hase 1-2 study of nivolumab, a PD-1 blocking monoclonal antibody, to determine its safety, pharmacoki

255 n combination with an anti-GD2 or anti-4-1BB monoclonal antibody, which resulted in increase in survi

256 ts of large, therapeutic proteins, such as a monoclonal antibody.

257 re abolished by pre-treatment with the GFRAL monoclonal antibody.

258 and of a much smaller fluorescently labeled monoclonal antibody.

259 in complex with a broadly neutralizing human monoclonal antibody.

260 We examined MG patient-derived monoclonal autoantibodies (mAbs), their corresponding ge

261 turation library on the surface of 8 million monoclonal beads.

262 RS-CoV-2 infectivity, an effect blocked by a monoclonal blocking antibody against NRP1.

263 rs frequently consist of oligoclonal to near-monoclonal clusters of intact proviral sequences.

264 chaeal genomes were reconstructed from pure (monoclonal) cultures, and the first reported sequences w

265 The use of monoclonals directed at the FcRn can rapidly enhance the

266 oscopy (cryo-EM) structure of a neutralizing monoclonal Fab-spike complex revealed an epitope that bl

267 he rate and predictors of finding lesions of monoclonal gammopathy (MG) of renal significance (MGRS)

268 symptoms are always preceded by a detectable monoclonal gammopathy and by elevated biomarkers of orga

269 tologists can screen subjects who have known monoclonal gammopathy for amyloid organ dysfunction and

270 It focuses on the concept of monoclonal gammopathy of clinical significance, which ca

271 noproliferative disorder that we have termed monoclonal gammopathy of macular significance.

272 Monoclonal gammopathy of undetermined significance (MGUS

273 rasias, including asymptomatic states called monoclonal gammopathy of undetermined significance and s

274 sionally may be the presenting feature); and monoclonal gammopathy of undetermined significance with

275 increased in both multiple myeloma (MM) and monoclonal gammopathy of undetermined significance, sugg

276 olyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome

277 iocytosis is a rare disorder associated with monoclonal gammopathy.

278 vated erythropoietin and erythrocytosis; (3) monoclonal gammopathy; (4) perinephric fluid collections

279 In this disease, monoclonal heavy and light chains accumulate in the lyso

280 We first identified a humanized monoclonal IgG that has a high binding affinity and a re

281 All patients had serum monoclonal IgM gammopathy (median, 2.6 g/L; range, 0.1-4

282 FR inhibitors as enhancers of the inhibitory monoclonal IL6 receptor antibody tocilizumab.

283 disease remains unclear, but the role of the monoclonal immunoglobulin (Ig) light chain (LC) is stron

284 ular and peritubular amorphous deposits of a monoclonal immunoglobulin LC, leading to nodular glomeru

285 in amyloidosis (AL), fibrillar deposition of monoclonal immunoglobulin light chains (LCs) in vital or

286 nce of a small B-cell clone, responsible for monoclonal immunoglobulin production.

287 ly described mass spectrometry method termed monoclonal immunoglobulin rapid accurate mass measuremen

288 Monoclonal KoH bodies have properties similar to those o

289 y region sequencing and a recently generated monoclonal line of conditionally immortalized rat atrial

290 rders (cMCD), systemic mastocytosis (SM) and monoclonal mast cell activation syndrome (MMAS), represe

291 disorders such as systemic mastocytosis and monoclonal MC activation syndrome were negative.

292 y than human IgG antibodies or infliximab (a monoclonal mouse-human chimeric IgG).

293 Cetuximab, a monoclonal neutralizing antibody against EGFR, blocks HI

294 n Polyneuropathy Organomegaly Endocrinopathy Monoclonal-protein and Skin Changes (POEMS) syndrome.

295 ons of natural TCRs (e.g., immune-mobilizing monoclonal T cell receptors against cancer [ImmTAC] mole

296 Immune mobilizing monoclonal T Cell receptors against virus (ImmTAV) molec

297 pathway and others may subsequently lead to monoclonal T-cell proliferation and clinical BIA-ALCL.

298 plore the novel modifications of therapeutic monoclonals that exploit FcRn functions to enhance thera

299 As SpliMLiB beads are monoclonal, they were amenable to direct functional scre

300 pecific VHH-Fcs or combination of individual monoclonal VHH-Fcs.